In contrast, in acute lymphoblastic leukemia, the promoter of FSP1 is hypermethylated to silence its expression and evolve a selective dependence on GSH-centered anti-ferroptosis defenses (Pontel et al, 2022). Here, AIFM2 is linked to acute lymphoblastic leukemia.